跳转至内容
Merck
CN

D7071

达泊西汀 盐酸盐

≥98% (HPLC)

别名:

(S)-(+)-N,N-二甲基-1-苯基-3-(1-萘氧基)丙胺盐酸盐, (S)-(+)-N,N-二甲基-a-[2-(萘氧基)乙基]苯甲胺盐酸盐,LY-210448 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C21H23NO · HCl
化学文摘社编号:
分子量:
341.87
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +125 to +135°, c = 1 in methanol

storage condition

desiccated

color

white

solubility

DMSO: ≥20 mg/mL

originator

Eli Lilly

storage temp.

room temp

SMILES string

Cl.CN(C)[C@@H](CCOc1cccc2ccccc12)c3ccccc3

InChI

1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1

InChI key

IHWDIQRWYNMKFM-BDQAORGHSA-N

Gene Information

human ... SLC6A4(6532)

General description

达泊西汀((+)-(S)-N,N-二甲基-(α)-[2(1萘氧基)乙基]-苯甲胺盐酸盐)的结构类似于氟西汀。

Biochem/physiol Actions

达泊西汀可阻断重组Kv4.3电压门控钾通道。已确认为安全的治疗药物。
有效的选择性5-羟色胺再摄取抑制剂(SSRI);用于治疗早泄
有效的选择性SSRI

Features and Benefits

该化合物收录于 受体分类和信号转导手册的《生物胺转运体 》页面。想要浏览手册的其他页面, 请单击此处
该化合物由Eli Lilly开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

W J G Hellstrom
International journal of clinical practice, 65(1), 16-26 (2010-12-16)
Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest. In 2008, the International Society for Sexual Medicine published an evidence-based definition for PE. While there are no US Food and Drug Administration-approved therapies for PE
Shiwei Tang et al.
Advances in therapy, 36(8), 2096-2105 (2019-05-31)
Factors that impact the pharmacokinetics of dapoxetine, a 5-HT selective reuptake inhibitor used for the treatment of premature ejaculation, have not been clearly identified. This study aimed to evaluate the effects of consumption of a high-fat meal and cytochrome P450
Nicola Mondaini et al.
Urology, 82(3), 620-624 (2013-08-31)
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment
Chris G McMahon et al.
The journal of sexual medicine, 8(2), 524-539 (2010-11-10)
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries. To present integrated efficacy and safety data from phase 3 trials
Imju Jeong et al.
Naunyn-Schmiedeberg's archives of pharmacology, 385(7), 707-716 (2012-04-28)
The effects of dapoxetine were examined on cloned Kv1.5 channels stably expressed in Chinese hamster ovary cells using the whole-cell patch clamp technique. Dapoxetine decreased the peak amplitude of Kv1.5 currents and accelerated the decay rate of current inactivation in

全球贸易项目编号

货号GTIN
D7071-50MG04061833588185
D7071-10MG04061833588178

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持